المؤلفون: Matsushita, Kensuke, Delmas, Clément, Marchandot, Benjamin, Roubille, François, Lamblin, Nicolas, Leurent, Guillaume, Levy, Bruno, Elbaz, Meyer, Champion, Sebastien, Lim, Pascal, Schneider, Francis, Khachab, Hadi, Carmona, Adrien, Trimaille, Antonin, Bourenne, Jeremy, Seronde, Marie‐france, Schurtz, Guillaume, Harbaoui, Brahim, Vanzetto, Gerald, Biendel, Caroline, Labbe, Vincent, Combaret, Nicolas, Mansourati, Jacques, Filippi, Emmanuelle, Maizel, Julien, Merdji, Hamid, Lattuca, Benoit, Gerbaud, Edouard, Bonnefoy, Eric, Puymirat, Etienne, Bonello, Laurent, Morel, Olivier

المساهمون: Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Casdiovasculaires (UPS/Inserm U1297 - I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre de recherche Cardio-Thoracique de Bordeaux Bordeaux (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Marseille (APHM), The study was sponsored by the Fédération Française de Cardiologie and was funded by unrestricted grants from Daiichi‐Sankyo and Maquet SAS. Complementary grants will be sought for dedicated research projects within the main study.

المصدر: ISSN: 2047-9980 ; Journal of the American Heart Association ; https://hal.science/hal-04474986Test ; Journal of the American Heart Association, 2024, 13 (5), pp.e030975. ⟨10.1161/JAHA.123.030975⟩.

مصطلحات موضوعية: cardiogenic shock, guideline‐directed medical therapy, heart failure, left ventricular ejection fraction, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.IB]Life Sciences [q-bio]/Bioengineering

الوصف: International audience ; Background The effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Thus, this study investigated the association between guideline‐directed heart failure (HF) medical therapy (GDMT) and one‐year survival rate in patients who are post‐CS. Methods and Results FRENSHOCK (French Observatory on the Management of Cardiogenic Shock in 2016) registry was a prospective multicenter observational survey, conducted in metropolitan French intensive care units and intensive cardiac care units. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in‐hospital deaths and 20 patients with missing medical records. Patients with triple GDMT (beta‐blockers, renin‐angiotensin system inhibitors, and mineralocorticoid receptor antagonists) at discharge (n=112) were likely to have lower left ventricular ejection fraction on admission and at discharge compared with those without triple GDMT (n=423) (22% versus 28%, P <0.001 and 29% versus 37%, P <0.001, respectively). In the overall cohort, the one‐year mortality rate was 23%. Triple GDMT prescription was significantly associated with a lower one‐year all‐cause mortality compared with non‐triple GDMT (adjusted hazard ratio 0.44 [95% CI, 0.19–0.80]; P =0.007). Similarly, 2:1 propensity score matching and inverse probability treatment weighting based on the propensity score demonstrated a lower incidence of one‐year mortality in the triple GDMT group. As the number of HF drugs increased, a stepwise decrease in mortality was observed (log rank; P <0.001). Conclusions In survivors of CS, the one‐year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38390813; hal-04474986; https://hal.science/hal-04474986Test; https://hal.science/hal-04474986/documentTest; https://hal.science/hal-04474986/file/2024%20Matsushita%20et%20al.,%20Optimal%20Heart%2024p.pdfTest; PUBMED: 38390813

الإتاحة: https://doi.org/10.1161/JAHA.123.030975Test
https://hal.science/hal-04474986Test
https://hal.science/hal-04474986/documentTest
https://hal.science/hal-04474986/file/2024%20Matsushita%20et%20al.,%20Optimal%20Heart%2024p.pdfTest

المؤلفون: Guénégou-Arnoux, Armelle, Murris, Juliette, Bechet, Stéphane, Jung, Camille, Auchabie, Johann, Dupeyrat, Julien, Anguel, Nadia, Asfar, Pierre, Badie, Julio, Carpentier, Dorothée, Chousterman, Benjamin, Bourenne, Jeremy, Delbove, Agathe, Devaquet, Jérôme, Deye, Nicolas, Dumas, Guillaume, Dureau, Anne-Florence, Lascarrou, Jean-Baptiste, Legriel, Stephane, Guitton, Christophe, Jannière-Nartey, Caroline, Quenot, Jean-Pierre, Lacherade, Jean-Claude, Maizel, Julien, Mekontso Dessap, Armand, Mourvillier, Bruno, Petua, Philippe, Plantefeve, Gaetan, Richard, Jean-Christophe, Robert, Alexandre, Saccheri, Clément, Vong, Ly van Phach, Katsahian, Sandrine, Schortgen, Frédérique

المساهمون: CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Unité de Recherche Clinique et Centre Investigation Clinique-Epidémiologie, Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Health data- and model- driven Knowledge Acquisition (HeKA), Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), PIERRE FABRE, Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Centre Hospitalier Intercommunal de Créteil (CHIC), Centre Hospitalier de Cholet (CH Cholet), Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Nord Franche-Comté Hôpital de Trévenans (HNFC), CHU Rouen, Normandie Université (NU), Hôpital Lariboisière-Fernand-Widal APHP, Hôpital de la Timone CHU - APHM (TIMONE), Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Hôpital Foch Suresnes, Service de Réanimation Médicale et Toxicologique Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal APHP, Hôpital Michallon, Groupe hospitalier de la région de Mulhouse et Sud-Alsace, Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Service de réanimation CH Versailles, Centre Hospitalier de Versailles André Mignot (CHV), Service Réanimation médico-chirurgicale CH Le Mans, Centre Hospitalier Le Mans (CH Le Mans), Centre Hospitalier Libourne, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Médecine Intensive-Réanimation CHU Amiens, CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Henri Mondor Créteil, Hôpital universitaire Robert Debré Reims (CHU Reims), Centre Hospitalier de Bigorre Tarbes, Centre hospitalier Argenteuil (CH Argenteuil), Université de Lyon, Hôpital Pasteur Nice (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Grand Hôpital de l'Est Francilien (GHEF), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), The study is funded by the French health ministry and was approved by the ethics committee CPP Nord Ouest II (Amiens, France).

المصدر: ISSN: 2044-6055 ; BMJ Open ; https://hal.science/hal-04505165Test ; BMJ Open, 2024, 14 (1), pp.e069430. ⟨10.1136/bmjopen-2022-069430⟩.

مصطلحات موضوعية: Adult intensive & critical care, Clinical trial, Intensive & critical care, Statistics & research methods, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصف: International audience ; Introduction Fever treatment is commonly applied in patients with sepsis but its impact on survival remains undetermined. Patients with respiratory and haemodynamic failure are at the highest risk for not tolerating the metabolic cost of fever. However, fever can help to control infection. Treating fever with paracetamol has been shown to be less effective than cooling. In the SEPSISCOOL pilot study, active fever control by external cooling improved organ failure recovery and early survival. The main objective of this confirmatory trial is to assess whether fever control at normothermia can improve the evolution of organ failure and mortality at day 60 of febrile patients with septic shock. This study will compare two strategies within the first 48 hours of septic shock: treatment of fever with cooling or no treatment of fever. Methods and analysis SEPSISCOOL II is a pragmatic, investigator-initiated, adaptive, multicentre, open-label, randomised controlled, superiority trial in patients admitted to the intensive care unit with febrile septic shock. After stratification based on the acute respiratory distress syndrome status, patients will be randomised between two arms: (1) cooling and (2) no cooling. The primary endpoint is mortality at day 60 after randomisation. The secondary endpoints include the evolution of organ failure, early mortality and tolerance. The target sample size is 820 patients. Ethics and dissemination The study is funded by the French health ministry and was approved by the ethics committee CPP Nord Ouest II (Amiens, France). The results will be submitted for publication in peer-reviewed journals. Trial registration number NCT04494074 .

العلاقة: hal-04505165; https://hal.science/hal-04505165Test; https://hal.science/hal-04505165/documentTest; https://hal.science/hal-04505165/file/e069430.full.pdfTest

الإتاحة: https://doi.org/10.1136/bmjopen-2022-069430Test
https://hal.science/hal-04505165Test
https://hal.science/hal-04505165/documentTest
https://hal.science/hal-04505165/file/e069430.full.pdfTest

المؤلفون: Titeca-Beauport, Dimitri, Diouf, Momar, Daubin, Delphine, Vong, Ly Van, Belliard, Guillaume, Bruel, Cédric, Zerbib, Yoann, Vinsonneau, Christophe, Klouche, Kada, Maizel, Julien

المساهمون: CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Groupe Hospitalier Sud Ile-de-France (GHSIF), Groupe Hospitalier Bretagne Sud (GHBS), Centre Hospitalier de Béthune (CH Béthune), GHT de l'Artois, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)

المصدر: ISSN: 0886-022X.

مصطلحات موضوعية: Acute kidney injury, biomarkers, cluster, phenotype, septic shock, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: International audience ; Background: The severity and course of sepsis-associated acute kidney injury (SA-AKI) are correlated with the mortality rate. Early detection of SA-AKI subphenotypes might facilitate the rapid provision of individualized care.Patients and methods: In this post-hoc analysis of a multicenter prospective study, we combined conventional kidney function variables with serial measurements of urine (tissue inhibitor of metalloproteinase-2 [TIMP-2])* (insulin-like growth factor-binding protein [IGFBP7]) at 0, 6, 12, and 24 h) and then using an unsupervised hierarchical clustering of principal components (HCPC) approach to identify different phenotypes of SA-AKI. We then compared the subphenotypes with regard to a composite outcome of in-hospital death or the initiation of renal replacement therapy (RRT).Results: We included 184 patients presenting SA-AKI within 6 h of the initiation of catecholamines. Three distinct subphenotypes were identified: subphenotype A (99 patients) was characterized by a normal urine output (UO), a low SCr and a low [TIMP-2]*[IGFBP7] level; subphenotype B (74 patients) was characterized by existing chronic kidney disease (CKD), a higher SCr, a low UO, and an intermediate [TIMP-2]*[IGFBP7] level; and subphenotype C was characterized by very low UO, a very high [TIMP-2]*[IGFBP7] level, and an intermediate SCr level. With subphenotype A as the reference, the adjusted hazard ratio (aHR) [95%CI] for the composite outcome was 3.77 [1.92-7.42] (p < 0.001) for subphenotype B and 4.80 [1.67-13.82] (p = 0.004) for subphenotype C.Conclusions: Combining conventional kidney function variables with urine measurements of [TIMP-2]*[IGFBP7] might help to identify distinct SA-AKI subphenotypes with different short-term courses and survival rates.

العلاقة: hal-04492244; https://hal.science/hal-04492244Test; https://hal.science/hal-04492244/documentTest; https://hal.science/hal-04492244/file/2024Titicea-Beauport%20et%20al.pdfTest

الإتاحة: https://doi.org/10.1080/0886022X.2024.2325640Test
https://hal.science/hal-04492244Test
https://hal.science/hal-04492244/documentTest
https://hal.science/hal-04492244/file/2024Titicea-Beauport%20et%20al.pdfTest

المؤلفون: Nseir, Saad, Martin-Loeches, Ignacio, Povoa, Pedro, Metzelard, Matthieu, Du Cheyron, Damien, Lambiotte, Fabien, Tamion, Fabienne, Labruyere, Marie, Makris, Demosthenes, Boulle Geronimi, Claire, Pinetonde Chambrun, Marc, Nyunga, Martine, Pouly, Olivier, Mégarbane, Bruno, Saade, Anastasia, Gomà, Gemma, Magira, Eleni, Llitjos, Jean-François, Torres, Antoni, Ioannidou, Iliana, Pierre, Alexandre, Coelho, Luis, Reignier, Jean, Garot, Denis, Kreitmann, Louis, Baudel, Jean-Luc, Voiriot, Guillaume, Contou, Damien, Beurton, Alexandra, Asfar, Pierre, Boyer, Alexandre, Thille, Arnaud, Mekontso-Dessap, Armand, Tsolaki, Vassiliki, Vinsonneau, Christophe, Floch, Pierre-Edouard, Le Guennec, Loïc, Ceccato, Adrian, Artigas, Antonio, Bouchereau, Mathilde, Labreuche, Julien, Duhamel, Alain, Rouzé, Anahita, Favory, Raphaël, Préau, Sébastien, Jourdain, Mercé, Poissy, Julien, Leger, Piehr Saint, van der Linden, Thierry, Veinstein, Anne, Azoulay, Elie, Pene, Frédéric, Martin, Maelle, Razazi, Keyvan, Plantefeve, Gaëtan, Fartoukh, Muriel, Thevenin, Didier, Guidet, Bertrand, Weiss, Nicolas, Kouatchet, Achille, Salmon, Charlotte, Brunin, Guillaume, Nemlaghi, Safaa, Meguerditchian, David, Argaud, Laurent, Voicu, Sebastian, Luyt, Charles-Edouard, Kowalski, Benjamin, Moglia, Edgar, Morales, Luis, Koutsoukou, Antonia, Mentzelopoulos, Spyros, Nora, David, Boyd, Sean, Maizel, Julien, Cuchet, Pierre, Delforge, Quentin, Quenot, Jean-Pierre, Boyer, Déborah, Cilloniz, Catia

المساهمون: Université de Lille, CHU Lille, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 RID-AGE, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576

مصطلحات موضوعية: Ventilator-associated pneumonia, Mortality, COVID-19

الوصف: Background Patients with SARS-CoV-2 infection are at higher risk for ventilator-associated pneumonia (VAP). No study has evaluated the relationship between VAP and mortality in this population, or compared this relationship between SARS-CoV-2 patients and other populations. The main objective of our study was to determine the relationship between VAP and mortality in SARS-CoV-2 patients. Methods Planned ancillary analysis of a multicenter retrospective European cohort. VAP was diagnosed using clinical, radiological and quantitative microbiological criteria. Univariable and multivariable marginal Cox’s regression models, with cause-specific hazard for duration of mechanical ventilation and ICU stay, were used to compare outcomes between study groups. Extubation, and ICU discharge alive were considered as events of interest, and mortality as competing event. Findings Of 1576 included patients, 568 were SARS-CoV-2 pneumonia, 482 influenza pneumonia, and 526 no evidence of viral infection at ICU admission. VAP was associated with significantly higher risk for 28-day mortality in SARS-CoV-2 group (adjusted HR 1.65 (95% CI 1.11–2.46), p = 0.013), but not in influenza (1.74 (0.99–3.06), p = 0.052), or no viral infection groups (1.13 (0.68–1.86), p = 0.63). VAP was associated with significantly longer duration of mechanical ventilation in the SARS-CoV-2 group, but not in the influenza or no viral infection groups. VAP was associated with significantly longer duration of ICU stay in the 3 study groups. No significant difference was found in heterogeneity of outcomes related to VAP between the 3 groups, suggesting that the impact of VAP on mortality was not different between study groups. Interpretation VAP was associated with significantly increased 28-day mortality rate in SARS-CoV-2 patients. However, SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, did not significantly modify the relationship between VAP and 28-day mortality. Clinical trial registration The study was registered ...

وصف الملف: application/octet-stream

العلاقة: Critical Care; Crit Care; http://hdl.handle.net/20.500.12210/109290Test

الإتاحة: https://doi.org/20.500.12210/109290Test
https://hdl.handle.net/20.500.12210/109290Test

المؤلفون: Reignier, Jean, Plantefève, Gaëtan, Mira, Jean-Paul, Argaud, Laurent, Asfar, Pierre, Aissaoui, Nadia, Badie, Julio, Botoc, Nicolae-Vlad, Brisard, Laurent, Bui, Hoang-Nam, Chatellier, Delphine, Chauvelot, Louis, Combes, Alain, Cracco, Christophe, Darmon, Michaël, Das, Vincent, Debarre, Matthieu, Delbove, Agathe, Devaquet, Jérôme, Dumont, Louis-Marie, Gontier, Olivier, Groyer, Samuel, Guérin, Laurent, Guidet, Bertrand, Hourmant, Yannick, Jaber, Samir, Lambiotte, Fabien, Leroy, Christophe, Letocart, Philippe, Madeux, Benjamin, Maizel, Julien, Martinet, Olivier, Martino, Frédéric, Maxime, Virginie, Mercier, Emmanuelle, Nay, Mai-Anh, Nseir, Saad, Oziel, Johanna, Picard, Walter, Piton, Gaël, Quenot, Jean-Pierre, Reizine, Florian, Renault, Anne, Richecoeur, Jack, Rigaud, Jean-Philippe, Schneider, Francis, Silva, Daniel, Sirodot, Michel, Souweine, Bertrand, Tamion, Fabienne, Terzi, Nicolas, Thévenin, Didier, Thiery, Guillaume, Thieulot-Rolin, Nathalie, Timsit, Jean-François, Tinturier, François, Tirot, Patrice, Vanderlinden, Thierry, Vinatier, Isabelle, Vinsonneau, Christophe, Voicu, Sebastian, Lascarrou, Jean-Baptiste, Le Gouge, Amélie

المساهمون: Motricité, interactions, performance UR 4334 / Movement - Interactions - Performance (MIP), Le Mans Université (UM)-Nantes Université - UFR des Sciences et Techniques des Activités Physiques et Sportives (Nantes Univ - UFR STAPS), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre hospitalier Argenteuil (CH Argenteuil), Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Nord Franche-Comté Hôpital de Trévenans (HNFC), CH de Saint-Malo Broussais, Hôpital Guillaume-et-René-Laennec Saint-Herblain, Service de Réanimation Médicale CHU Bordeaux, CHU Bordeaux-Hôpital Pellegrin, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ), Hôpital de la Croix-Rousse CHU - HCL, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition CHU Pitié Salpêtrière (IHU ICAN), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier d'Angoulême (CH Angoulême), Hopital Saint-Louis AP-HP (AP-HP), Centre Hospitalier Intercommunal André Grégoire Montreuil (CHI André Gregoire), Centre hospitalier Saint-Brieuc, Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Hôpital Foch Suresnes, Hôpital Louis Mourier - AP-HP Colombes, Hôpitaux de Chartres Chartres, Centre hospitalier de Montauban (CH Montauban), Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Pharmacoépidémiologie et évaluation des soins iPLesp (PEPITES), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre hospitalier Valenciennes, Nord, Centre Hospitalier Emile Roux AP-HP, Hôpital Jacques Puel - Bourran Rodez (HJPB), Centre Hospitalier de Bigorre Tarbes, CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Unité de Soins Intensifs CHU La Réunion, Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), CHU Pointe-à-Pitre/Abymes Guadeloupe, Hôpital Raymond Poincaré (Garches) GHU AP-HP Université Paris-Saclay, Infection et inflammation (2I), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche sur l'interculturalité et la circulation médiatique des savoirs (CRICS (EA_3965)), Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 (UGSF), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Hôpital Avicenne AP-HP, Centre hospitalier de Pau, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc Dijon (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Etablissement français du sang Bourgogne-Franche-Comté (EFS BFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Université de Montpellier (UM), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard Paris, Université de Bourgogne (UB), Centre Hospitalier Universitaire Rennes, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Centre Hospitalier de Beauvais, Centre hospitalier de Dieppe, Les Hôpitaux Universitaires de Strasbourg (HUS), Hôpital Delafontaine, Centre Hospitalier de Saint-Denis Ile-de-France, Centre Hospitalier Annecy-Genevois Saint-Julien-en-Genevois, CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand, Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN)

المصدر: ISSN: 2213-2600.

مصطلحات موضوعية: [SDV]Life Sciences [q-bio]

الوصف: Also written with the NUTRIREA-3 Trial Investigators and the Clinical Research in Intensive Care and Sepsis (CRICS-TRIGGERSEP) Group ; International audience ; BackgroundThe optimal calorie and protein intakes at the acute phase of severe critical illness remain unknown. We hypothesised that early calorie and protein restriction improved outcomes in these patients, compared with standard calorie and protein targets.MethodsThe pragmatic, randomised, controlled, multicentre, open-label, parallel-group NUTRIREA-3 trial was performed in 61 French intensive care units (ICUs). Adults (≥18 years) receiving invasive mechanical ventilation and vasopressor support for shock were randomly assigned to early nutrition (started within 24 h after intubation) with either low or standard calorie and protein targets (6 kcal/kg per day and 0·2–0·4 g/kg per day protein vs 25 kcal/kg per day and 1·0–1·3 g/kg per day protein) during the first 7 ICU days. The two primary endpoints were time to readiness for ICU discharge and day 90 all-cause mortality. Key secondary outcomes included secondary infections, gastrointestinal events, and liver dysfunction. The trial is registered on ClinicalTrials.gov, NCT03573739, and is completed.FindingsOf 3044 patients randomly assigned between July 5, 2018, and 8 Dec 8, 2020, eight withdrew consent to participation. By day 90, 628 (41·3%) of 1521 patients in the low group and 648 (42·8%) of 1515 patients in the standard group had died (absolute difference –1·5%, 95% CI –5·0 to 2·0; p=0·41). Median time to readiness for ICU discharge was 8·0 days (IQR 5·0–14·0) in the low group and 9·0 days (5·0–17·0) in the standard group (hazard ratio [HR] 1·12, 95% CI 1·02 to 1·22; p=0·015). Proportions of patients with secondary infections did not differ between the groups (HR 0·85, 0·71 to 1·01; p=0·06). The low group had lower proportions of patients with vomiting (HR 0·77, 0·67 to 0·89; p<0·001), diarrhoea (0·83, 0·73 to 0·94; p=0·004), bowel ischaemia (0·50, 0·26 to 0·95; p=0·030), and liver dysfunction ...

العلاقة: hal-04042278; https://hal.science/hal-04042278Test; https://hal.science/hal-04042278/documentTest; https://hal.science/hal-04042278/file/2023%20Reigneir%20et%20al.,%20Low%20versus%20standard.pdfTest

الإتاحة: https://doi.org/10.1016/S2213-2600Test(23)00092-9
https://hal.science/hal-04042278Test
https://hal.science/hal-04042278/documentTest
https://hal.science/hal-04042278/file/2023%20Reigneir%20et%20al.,%20Low%20versus%20standard.pdfTest

المؤلفون: Lascarrou, Jean Baptiste, Bougouin, Wulfran, Chelly, Jonathan, Bourenne, Jeremy, Daubin, Cedric, Lesieur, Olivier, Asfar, Pierre, Colin, Gwenhael, Paul, Marine, Chudeau, Nicolas, Muller, Gregoire, Geri, Guillaume, Jacquier, Sophier, Pichon, Nicolas, Klein, Thomas, Sauneuf, Bertrand, Klouche, Kada, Cour, Martin, Sejourne, Caroline, Annoni, Filippo, Raphalen, Jean-Herle, Galbois, Arnaud, Bruel, Cedric, Mongardon, Nicolas, Aissaoui, Nadia, Deye, Nicolas, Maizel, Julien, Dumas, Florence, Legriel, Stephane, Cariou, Alain, Peres, Noémie, Le Saux, Audrey, Bellal, Mathieu, Leloup, Maxime, Jaubert, Paul, Henry-Lagarrigue, Matthieu, Alezra, Nina, Meunier, Juliette, Nay, Mai-Anh, Salmon-Gandonnière, Charlotte, Mons, Sandrine, Levy, Bruno, Souloy, Xavier, Platon, Laura, Argaud, Laurent, Taccone, Fabio, Vimpere, Damien, Chelha, Riad, de Roux, Quentin, Berlemont, Caroline Hauw, Megarbane, Bruno, Benghanem, Sarah, Lemarie, Jeremie, Goulenok, Cyril

المساهمون: Motricité, interactions, performance UR 4334 / Movement - Interactions - Performance (MIP), Le Mans Université (UM)-Nantes Université - UFR des Sciences et Techniques des Activités Physiques et Sportives (Nantes Univ - UFR STAPS), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), AfterROSC Network Group Paris, Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Privé Jacques Cartier Massy, Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse, Hôpital de la Timone CHU - APHM (TIMONE), Service de Soins Intensifs CHU Caen, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Groupe hospitalier de La Rochelle, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre Hospitalier de Versailles André Mignot (CHV), Centre Hospitalier Le Mans (CH Le Mans), Centre Hospitalier Régional d'Orléans (CHRO), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Ambroise Paré AP-HP, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier de Brive-la-Gaillarde (CH Brive), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Anesthésie et Réanimation CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CH Centre Hospitalier Public du Cotentin (CHPC), Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Hospices Civils de Lyon (HCL), Centre Hospitalier de Béthune (CH Béthune), GHT de l'Artois, Hôpital Erasme Bruxelles, Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Privé Claude Galien - Ramsay Santé, Groupe Hospitalier Paris Saint-Joseph (hpsj), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Lariboisière-Fernand-Widal APHP, CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Hôpital Cochin AP-HP

المصدر: ISSN: 2110-5820 ; Annals of Intensive Care ; https://u-picardie.hal.science/hal-04247479Test ; Annals of Intensive Care, 2023, 13 (1), pp.100. ⟨10.1186/s13613-023-01195-w⟩.

مصطلحات موضوعية: Cardiac arrest, Functional outcome, Neurological prognosis, Outcome prediction, Score, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصف: International audience ; Background Out-of-hospital cardiac arrest (OHCA) is a heterogeneous entity with multiple origins and prognoses. An early, reliable assessment of the prognosis is useful to adapt therapeutic strategy, tailor intensity of care, and inform relatives. We aimed primarily to undertake a prospective multicentric study to evaluate predictive performance of the Cardiac Arrest Prognosis (CAHP) Score as compare to historical dataset systematically collected after OHCA (Utstein style criteria). Our secondary aim was to evaluate other dedicated scores for predicting outcome after OHCA and to compare them to Utstein style criteria. Methods We prospectively collected data from 24 French and Belgium Intensive Care Units (ICUs) between August 2020 and June 2022. All cases of non-traumatic OHCA (cardiac and non-cardiac causes) patients with stable return of spontaneous circulation (ROSC) and comatose at ICU admission (defined by Glasgow coma score ≤ 8) on ICU admission were included. The primary outcome was the modified Rankin scale (mRS) at day 90 after cardiac arrest, assessed by phone interviews. A wide range of developed scores (CAHP, OHCA, CREST, C-Graph, TTM, CAST, NULL-PLEASE, and MIRACLE2) were included, and their accuracies in predicting poor outcome at 90 days after OHCA (defined as mRS ≥ 4) were determined using the area under the receiving operating characteristic curve (AUROC) and the calibration belt. Results During the study period, 907 patients were screened, and 658 were included in the study. Patients were predominantly male (72%), with a mean age of 61 ± 15, most having collapsed from a supposed cardiac cause (64%). The mortality rate at day 90 was 63% and unfavorable neurological outcomes were observed in 66%. The performance (AUROC) of Utstein criteria for poor outcome prediction was moderate at 0.79 [0.76–0.83], whereas AUROCs from other scores varied from 0.79 [0.75–0.83] to 0.88 [0.86–0.91]. For each score, the proportion of patients for whom individual values could not be ...

العلاقة: hal-04247479; https://u-picardie.hal.science/hal-04247479Test; https://u-picardie.hal.science/hal-04247479/documentTest; https://u-picardie.hal.science/hal-04247479/file/s13613-023-01195-w.pdfTest

الإتاحة: https://doi.org/10.1186/s13613-023-01195-wTest
https://u-picardie.hal.science/hal-04247479Test
https://u-picardie.hal.science/hal-04247479/documentTest
https://u-picardie.hal.science/hal-04247479/file/s13613-023-01195-w.pdfTest

المؤلفون: Declercq, Pierre-Louis, Fournel, Isabelle, Demeyere, Matthieu, Berraies, Anissa, Ksiazek, Eléa, Nyunga, Martine, Daubin, Cédric, Ampere, Alexandre, Sauneuf, Bertrand, Badie, Julio, Delbove, Agathe, Nseir, Saad, Artaud-Macari, Elise, Bironneau, Vanessa, Ramakers, Michel, Maizel, Julien, Miailhe, Arnaud-Felix, Lacombe, Béatrice, Delberghe, Nicolas, Oulehri, Walid, Georges, Hugues, Tchenio, Xavier, Clarot, Caroline, Redureau, Elise, Bourdin, Gaël, Federici, Laura, Adda, Mélanie, Schnell, David, Bousta, Mehdi, Salmon-Gandonnière, Charlotte, Vanderlinden, Thierry, Plantefeve, Gaëtan, Delacour, David, Delpierre, Cyrille, Le Bouar, Gurvan, Sedillot, Nicholas, Beduneau, Gaëtan, Rivière, Antoine, Meunier-Beillard, Nicolas, Gélinotte, Stéphanie, Rigaud, Jean-Philippe, Labruyère, Marie, Georges, Marjolaine, Binquet, Christine, Quenot, Jean-Pierre, Group, Crics-Triggersep, de Jesus, Mélody, Normant, Sébastien, Dacher, Jean-Nicolas, Stoup, Thomas, Vinsonneau, Christophe, Dewatine, Anne, Cuchet, Pierre, Rots, Delphine, Calus, Julien, Le Moel, Gabriel, Kalfon, Pierre, Badre, Gaëtan, Roy, Jean-François, Roux, Damien, Ricard, Jean-Damien, Marcq, Marie, Georges, Thomas, Pouplet, Caroline, Lagache, Laurie, Masson, Nicolas, Devos, Matthieu, Favory, Raphaël, Preau, Sébastien, Gaudet, Alexandre, Bouju, Pierre, Nichita, Lidia, Maignan, Pascal, Labourot, Laurence, Molinari, Francesco, Thirard, Laurence, Larrat, Charlotte, Berdaguer, Fernando, Akgun, Meltem Karakaya, Fedun, Yannick, Guy, Thiphaine, Gousseff, Marie, Boyer, Déborah, Bonnevie, Tristan, Demarest, Elsa, Hraiech, Sami, Sylvestre, Aude, Sanz, Céline, Veinstein, Anne

المساهمون: Centre hospitalier de Dieppe, Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie CHU Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre Hospitalier de Roubaix, Service d'Anesthésie - Réanimation Chirurgicale CHU Caen, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier de Béthune (CH Béthune), GHT de l'Artois, CH Centre Hospitalier Public du Cotentin (CHPC), Hôpital Nord Franche-Comté Hôpital de Trévenans (HNFC), Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Réanimation Médicale, CHU Lille, Lille, Service de pneumologie, oncologie thoracique et soins intensifs respiratoires Rouen, Hôpital Charles Nicolle Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ), Service de Soins Intensifs CHU Caen, CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Groupe Hospitalier Bretagne Sud (GHBS), Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier de Tourcoing, Centre Hospitalier Fleyriat Bourg en Bresse (CHBBF), Centre Hospitalier d'Abbeville, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre hospitalier Saint Joseph - Saint Luc Lyon, Hôpital Louis Mourier - AP-HP Colombes, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance Publique - Hôpitaux de Marseille (APHM), Centre Hospitalier d'Angoulême (CH Angoulême), Groupe Hospitalier du Havre, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Experience, Technology & Human Interactions, Care & Society : (ETHICS EA 7446), Institut Catholique de Lille (ICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Centre hospitalier Argenteuil (CH Argenteuil), Clinique du Cèdre - Bois Guillaume (France), Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Eure-Seine - Hôpital d'Evreux - Vernon (Evreux), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation Dijon (CSGA), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), the CRICS-TRIGGERSEP

المصدر: ISSN: 0342-4642.

مصطلحات موضوعية: [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصف: Correction: Intensive Care Medicine https://doi.org/10.1007/s00134-023-07180-yTest When this article was published, some final corrections were accidentally overlooked. They concerned the layout and some abbreviations in figures and tables. The content of the articles was not affected.The Original Article was published on 24 August 2023. ; International audience

العلاقة: hal-04221467; https://u-picardie.hal.science/hal-04221467Test; WOS: 001076562500001

الإتاحة: https://doi.org/10.1007/s00134-023-07217-2Test
https://u-picardie.hal.science/hal-04221467Test

المؤلفون: Chaïbi, Khalil, Ehooman, Franck, Pons, Bertrand, Martin-Lefevre, Laurent, Boulet, Eric, Boyer, Alexandre, Chevrel, Guillaume, Lerolle, Nicolas, Carpentier, Dorothée, de Prost, Nicolas, Lautrette, Alexandre, Bretagnol, Anne, Mayaux, Julien, Nseir, Saad, Megarbane, Bruno, Thirion, Marina, Forel, Jean-Marie, Maizel, Julien, Yonis, Hodane, Markowicz, Philippe, Thiery, Guillaume, Schortgen, Frédérique, Couchoud, Cécile, Dreyfuss, Didier, Gaudry, Stephane

المساهمون: Hôpital Avicenne AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Maladies rénales fréquentes et rares : des mécanismes moléculaires à la médecine personnalisée (CoRaKID), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pointe-à-Pitre/Abymes Guadeloupe, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre Hospitalier René Dubos Pontoise, Hôpital Pellegrin, CHU Bordeaux-Groupe hospitalier Pellegrin, Centre Hospitalier Sud Francilien, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Rouen, Normandie Université (NU), CHU Henri Mondor Créteil, Groupe de recherche clinique CARMAS (Cardiovascular and Respiratory Manifestations of Acute lung injury and Sepsis) (CARMAS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-CHU Henri Mondor Créteil, CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S 1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Lariboisière-Fernand-Widal APHP, Centre Hospitalier Victor Dupouy, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Hôpital Nord CHU - APHM, CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Hôpital de la Croix-Rousse CHU - HCL, Hospices Civils de Lyon (HCL), Centre Hospitalier de Cholet (CH Cholet), Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E), Centre Hospitalier Intercommunal de Créteil (CHIC), Registre REIN, Agence de la biomédecine Saint-Denis la Plaine, Hôpital Louis Mourier - AP-HP Colombes, Université Paris Cité (UPCité)

المصدر: ISSN: 2110-5820 ; Annals of Intensive Care ; https://u-picardie.hal.science/hal-04032380Test ; Annals of Intensive Care, 2023, 13 (1), pp.18. ⟨10.1186/s13613-023-01108-x⟩.

مصطلحات موضوعية: Acute kidney injury, Long-term outcomes, Renal replacement therapy, Worsening renal failure, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصف: International audience ; Abstract Background The extent of the consequences of an episode of severe acute kidney injury (AKI) on long-term outcome of critically ill patients remain debated. We conducted a prospective follow-up of patients included in a large multicenter clinical trial of renal replacement therapy (RRT) initiation strategy during severe AKI (the Artificial Kidney Initiation in Kidney Injury, AKIKI) to investigate long-term survival, renal outcome and health related quality of life (HRQOL). We also assessed the influence of RRT initiation strategy on these outcomes. Results Follow-up of patients extended from 60 days to a median of 3.35 years [interquartile range (IQR), 1.89 to 4.09] after the end of initial study. Of the 619 patients included in the AKIKI trial, 316 survived after 60 days. The overall survival rate at 3 years from inclusion was 39.4% (95% CI 35.4 to 43.4). A total of 46 patients (on the 175 with available data on long-term kidney function) experienced worsening of renal function (WRF) at the time of follow-up [overall incidence of 26%, cumulative incidence at 4 years: 20.6% (CI 95% 13.0 to 28.3)]. Fifteen patients required chronic dialysis (5% of patients who survived after day 90). Among the 226 long-term survivors, 80 (35%) answered the EQ-5D questionnaire. The median index value reported was 0.67 (IQR 0.40 to 1.00) indicating a noticeable alteration of quality of life. Initiation strategy for RRT had no effect on any long-term outcome. Conclusion Severe AKI in critically ill patients was associated with a high proportion of death within the first 2 months but less so during long-term follow-up. A quarter of long-term survivors experienced a WRF and suffered from a noticeable impairment of quality of life. Renal replacement therapy initiation strategy was not associated with mortality outcome. Graphical Abstract

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36907976; hal-04032380; https://u-picardie.hal.science/hal-04032380Test; https://u-picardie.hal.science/hal-04032380/documentTest; https://u-picardie.hal.science/hal-04032380/file/s13613-023-01108-x.pdfTest; PUBMED: 36907976; PUBMEDCENTRAL: PMC10008759

الإتاحة: https://doi.org/10.1186/s13613-023-01108-xTest
https://u-picardie.hal.science/hal-04032380Test
https://u-picardie.hal.science/hal-04032380/documentTest
https://u-picardie.hal.science/hal-04032380/file/s13613-023-01108-x.pdfTest

المؤلفون: Trøseid, Marius, Arribas, José, Assoumou, Lambert, Holten, Aleksander Rygh, Poissy, Julien, Terzić, Vida, Mazzaferri, Fulvia, Baño, Jesús Rodríguez, Eustace, Joe, Hites, Maya, Joannidis, Michael, Paiva, José-Artur, Reuter, Jean, Püntmann, Isabel, Patrick-Brown, Thale, Westerheim, Elin, Nezvalova-Henriksen, Katerina, Beniguel, Lydie, Dahl, Tuva Børresdatter, Bouscambert, Maude, Halanova, Monika, Péterfi, Zoltán, Tsiodras, Sotirios, Rezek, Michael, Briel, Matthias, Ünal, Serhat, Schlegel, Martin, Ader, Florence, Lacombe, Karine, Amdal, Cecilie Delphin, Rodrigues, Serge, Tonby, Kristian, Gaudet, Alexandre, Heggelund, Lars, Mootien, Joy, Johannessen, Asgeir, Møller, Jannicke Horjen, Pollan, Beatriz Diaz, Tveita, Anders Aune, Kildal, Anders Benjamin, Richard, Jean-Christophe, Dalgard, Olav, Simensen, Victoria Charlotte, Baldé, Aliou, de Gastines, Lucie, del Álamo, Marta, Aydin, Burç, Lund-Johansen, Fridtjof, Trabaud, Mary-Anne, Diallo, Alpha, Halvorsen, Bente, Røttingen, John-Arne, Tacconelli, Evelina, Yazdanpanah, Yazdan, Olsen, Inge, Costagliola, Dominique, Dyrhol-Riise, Anne Ma, Stiksrud, Birgitte, Jenum, Synne, Macpherson, Magnhild Eide, Aarskog, Nikolai Ravn, Røstad, Kjerstin, Skeie, Linda Gail, Dahl, Åsne, Steen, Jeanette Konstance, Nur, Sarah, Segers, Filip, Korsan, Katrine Andersen, Sethupathy, Ashwini, Sandstå, Ann Jorunn, Paulsen, Gunn-Janne, Ueland, Thor, Michelsen, Annika, Aukrust, Pål, Berdal, Jan Erik, Melkeraaen, Ingunn, Tollefsen, Merete Moen, Andreassen, Jessica, Dokken, Jannicke, Müller, Karl Erik, Woll, Bjørn Martin, Opsand, Hanne, Bogen, Mette, Rød, Linn-Therese, Steinsvik, Trude, Åsheim-Hansen, Bjørn, Bjerkreim, Randi Haukaas, Berg, Åse, Moen, Solfrid, Kvalheim, Stina, Strand, Kristian, Gravrok, Berit, Skogen, Vegard, Lorentzen, Elias Myrvoll, Schive, Simen Walberg, Rossvoll, Lasse, Hoel, Hedda, Engebråten, Simon, Martinsson, Mia Schie, Thallinger, Monica, Ådnanes, Elise, Hannula, Raisa, Bremnes, Nina, Liyanarachi, Kristin, Ehrnström, Birgitta, Kvalshaug, Martin, Berge, Kari, Bygdås, Marte, Gustafsson, Linda, Aballib, Saad, Strand, Marianne, Andersen, Britt, Barratt-Due, Andreas, Henriksen, Katerina Nezvalova, Kåsine, Trine, Favory, Raphaël, Nseir, Saad, Preau, Sebastien, Jourdain, Mercé, Ledoux, Geoffrey, Durand, Arthur, Houard, Marion, Moreau, Anne-Sophie, Rouzé, Anahita, Tortuyaux, Romain, Degouy, Guillaume, Levy, Clémentin, Liu, Vincent, Dognon, Nicolas, Mariller, Laure, Delcourte, Claire, Reguig, Zineb, Cerf, Amélie, Cuvelliez, Marie, Kipnis, Eric, Boyer-Beysserre, Marielle, Bignon, Anne, Parmentier, Laurie, Meddour, Damia, Frade, Sarah, Timsit, Jean-François, Peiffer-Smadja, Nathan, Wicky, Paul-Henri, de Montmollin, Etienne, Bouadma, Lila, Dessajan, Julien, Sonneville, Romain, Patrier, Juliette, Presente, Simona, Sylia, Zmihi, Rioux, Christophe, Thy, Michaël, Collias, Lio, Bouaraba, Yasmine, Dobremel, Nikita, Dureau, Anne-Florence, Oudeville, Pierre, Pointurier, Valentin, Rabouel, Yannick, Stiel, Laure, Alzina, Camille, Ramstein, Camille, Ait-Oufella, Hafid, Hamoudi, Fatima, Urbina, Thomas, Zerbib, Yoann, Maizel, Julien, Wilpotte, Celine, Piroth, Lionel, Blot, Mathieu, Sixt, Thibault, Moretto, Florian, Charles, Carole, Gohier, Sandrine, Roux, Damien, Le Breton, Camille, Gernez, Coralie, Thiry, Ingrid, Baboi, Loredana, Malvy, Denis, Boyer, Alexandre, Perreau, Pauline, Armellini, Maddalena, de Luca, Giulia, Di Pietro, Ospedale, Romanin, Benedetta, Brogi, Michela, Castelli, Francesco, Amadasi, Silvia, Barchiesi, Francesco, Canovari, Benedetta, Coppola, Nicola, Pisaturo, Mariantonietta, Russo, Antonio, Occhiello, Laura, Cataldo, Francesco, Rillo, Marta Mora, Queiruga, Javier, Seco, Enrique, Stewart, Stefan, Borobia, Alberto, Moraga, Paloma, Prieto, Rocío, García, Irene, Rivera, Carlota, Narro, José Luis, Chacón, Natalia, de la Rosa, Sandra, Macías, María, Barrera, Lydia, Serna, Almudena, Palomo, Virginia, Sánchez, Maria Isabel García, Gutiérrez, David, Campos, Ana Silva, Garfia, Miguel Ángel Gómez, Toyos, Elvira Bonilla, Cabrera, Judith Sanabria, Lucena, María Isabel, Lapique, Eva Larranaga, Englert, Pierre, Khalil, Zineb, Jacobs, Frédérique, Malaise, Justine, Mukangenzi, Odette, Smissaert, Cinderella, Hildebrand, Marc, Martiny, Delphine, Vervacke, Audrey, Scarnière, Axelle, Yin, Nicolas, Michel, Charlotte, Seyler, Lucie, Allard, Sabine, van Laethem, Johan, Verschelden, Gil, Meeuwissen, Annelies, de Waele, Alex, van Buggenhout, Virgini, Monteyne, Dora, Noppe, Nils, Belkhir, Leila, Yombi, Jean Cyr, de Greef, Julien, Mesland, Jean Baptiste, de Ghellinck, Léopold, Kin, Valérie, D’aoust, Céline, Bouvier, Anne, Dekeister, Anne- Charlotte, Hawia, Estelle, Gaillet, Adeline, Deshorme, Hélène, Halleux, Severine, Galand, Vanessa, Roncon-Albuquerque, Roberto, Santos, Luís Linhares, Vieira, César Burgi, Magalhaes, Rosana, Ferreira, Sónia, Bernardo, Mariana, Jackson, Arthur, Sadlier, Corinna, O’connell, Sarah, Blair, Matthew, Manning, Edmund, Cusack, Fiona, Kelly, Niamh, Stephenson, Hannah, Keane, Ruben, Murphy, Aisling, Cunnane, Michele, Keane, Fionnuala, O’regan, Mary-Claire, de Barra, Eoghan, Bellone, Aimee Mcgreal, O’regan, Siobhan, Carey, Patrick, Harte, Jeffrey, Coakley, Peter, Heeney, Aoife, Ryan, Dorothy, Curley, Gerard, Mcconkey, Samuel, Sulaiman, Imran, Costello, Richard, Mcnally, Cora, Foley, Claire, Trainor, Sophie, Jacob, Benson, Vengathodi, Suchitra, Kent, Brian, Bergin, Colm, Townsend, Liam, Kerr, Colm, Panti, Nalini, Sanz, Alberto Garcia, Benny, Binny, Dea, Edel, Galvin, Niamh, Burke, Claire, Galvin, Aisling, Aisiyabi, Sara, Lobo, Deepanjali, Laffey, John, Mcnicolas, Bairbre, Cosgrave, David, Sheehan, J., Nita, Ciprian, Hanley, Ciara, Kelly, Claire, Kernan, Maeve, Murray, Jonathan, Staub, Thérèse, Henin, Thomas, Damilot, Gaelle, Bintener, Tania, Colling, Joelle, Ferretti, Christian, Werer, Christophe, Stammet, Pascal, Braquet, Pierre, Arendt, Vic, Calvo, Esther, Michaux, Christian, Mediouni, Chouaib, Znati, Ali, Montanes, Gloria, Garcia, Laetitia, Thomé, Claudius, Breitkopf, Robert, Peer, Andreas, Lehner, Georg, Bellman, Romuald, Ditlbacher, Adelheid, Finkenstedt, Armin, Zotter, Klemens, Hernandez, Christian Preuss, Rajsic, Sasa, Lanthaler, Barbara, Greil, Richard, Tamás, Kiss, Kovácsné-Levang, Szilvia, Sipos, David, Kappéter, Agnes, Halda-Kiss, Bernadett, Madarassi-Papp, Edit, Hajdu, Edit, Bende, Balázs, Konstantinos, Thomas, Moschopoulos, Charalambos, Labrou, Eleni, Tsakona, Maria, Grigoropoulos, Ioannis, Kotanidou, Anastasia, Fragkou, Paraskevi, Theodorakopoulou, Maria, Pantazi, Eugenia, Jahai, Edison, Moukouli, Maria, Siafakas, Dimitrios, Mühlbauer, Bernd, Dembinski, Rolf, Stich, Kathrin, Schneider, Gerhard, Nagy, Andrej, Grodová, Karolína, Kubelová, Michaela, Součková, Lenka, Švábová, Helena Kartáková, Demlová, Regina, Sonderlichová, Simona, Unal, Serhat, Inkaya, A., de Bono, Stephanie, Kartman, Cynthia, Adams, David, Crowe, Brenda, Yazdanapanah, Yazdan, Ødegård, Tone, Bakkehøi, Gine, Autran, Brigitte, Bjørås, Magnar, Lambellerie, Xavier De-, Mezzarri, Fulvia, Guedj, Jeremie, Esperou, Helene, Lumbroso, Julia, Welte, Tobias, Calmy, Alexandra, Pischke, Søren, Treweek, Shaun, Goetghebeur, Els, Doussau, Adelaide, Weiss, Laurence, Hulstaert, Frank, Botgros, Radu, del Alamo, Marta, Chung, Florence, Zeitlinger, Markus, Escalera, Begonya, Csajka, Chantal, Williams, Clare, Amstutz, Alain, Rüegg, Corina Silvia, Burdet, Charles, Massonnaud, Clement, Belhadi, Drifa, Mentré, France, Aroun, Massinissa, Ehrmann, Stephan, Espoerou, Helene, Falk, Ragnhild Sørum, Bjordal, Kristin, Bakkehøi, Gina

المساهمون: Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille)

المصدر: ISSN: 1364-8535.

مصطلحات موضوعية: [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: International audience ; Abstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients with severe/critical COVID-19 were randomised to Baricitinib 4 mg once daily or placebo, added to standard of care. The primary endpoint was all-cause mortality within 60 days. Participants were remotely followed to day 90 for safety and patient related outcome measures. Results Two hundred ninety-nine patients were screened, 284 randomised, and 275 received study drug or placebo and were included in the modified intent-to-treat analyses (139 receiving baricitinib and 136 placebo). Median age was 60 (IQR 49–69) years, 77% were male and 35% had received at least one dose of SARS-CoV2 vaccine. There were 21 deaths at day 60 in each group, 15.1% in the baricitinib group and 15.4% in the placebo group (adjusted absolute difference and 95% CI − 0.1% [− 8·3 to 8·0]). In sensitivity analysis censoring observations after drug discontinuation or rescue therapy (tocilizumab/increased steroid dose), proportions of death were 5.8% versus 8.8% (− 3.2% [− 9.0 to 2.7]), respectively. There were 148 serious adverse events in 46 participants (33.1%) receiving baricitinib and 155 in 51 participants (37.5%) receiving placebo. In subgroup analyses, there was a potential interaction between vaccination status and treatment allocation on 60-day mortality. In a subsequent post hoc analysis there was a significant interaction between vaccination status and treatment allocation on the occurrence of serious adverse events, with more respiratory complications and severe infections in vaccinated participants treated with baricitinib. Vaccinated participants were on average 11 years older, with more ...

العلاقة: hal-04399266; https://hal.science/hal-04399266Test; https://hal.science/hal-04399266/documentTest; https://hal.science/hal-04399266/file/s13054-022-04205-8.pdfTest

الإتاحة: https://doi.org/10.1186/s13054-022-04205-8Test
https://hal.science/hal-04399266Test
https://hal.science/hal-04399266/documentTest
https://hal.science/hal-04399266/file/s13054-022-04205-8.pdfTest

المؤلفون: Declercq, Pierre-Louis, Fournel, Isabelle, Demeyere, Matthieu, Berraies, Anissa, Ksiazek, Eléa, Nyunga, Martine, Daubin, Cédric, Ampere, Alexandre, Sauneuf, Bertrand, Badie, Julio, Delbove, Agathe, Nseir, Saad, Artaud-Macari, Elise, Bironneau, Vanessa, Ramakers, Michel, Maizel, Julien, Miailhe, Arnaud-Felix, Lacombe, Béatrice, Delberghe, Nicolas, Oulehri, Walid, Georges, Hugues, Tchenio, Xavier, Clarot, Caroline, Redureau, Elise, Bourdin, Gaël, Federici, Laura, Adda, Mélanie, Schnell, David, Bousta, Mehdi, Salmon-Gandonnière, Charlotte, Vanderlinden, Thierry, Plantefeve, Gaëtan, Delacour, David, Delpierre, Cyrille, Le Bouar, Gurvan, Sedillot, Nicholas, Beduneau, Gaëtan, Rivière, Antoine, Meunier-Beillard, Nicolas, Gélinotte, Stéphanie, Rigaud, Jean-Philippe, Labruyère, Marie, Georges, Marjolaine, Binquet, Christine, Quenot, Jean-Pierre, De Jesus, Mélody, Normant, Sébastien, Dacher, Jean-Nicolas, Stoup, Thomas, Vinsonneau, Christophe

المصدر: Intensive Care Medicine ; volume 49, issue 10, page 1168-1180 ; ISSN 0342-4642 1432-1238

مصطلحات موضوعية: Critical Care and Intensive Care Medicine

الإتاحة: https://doi.org/10.1007/s00134-023-07180-yTest